Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Synopsis of current research projects
                          • Synopsis of completed research projects
                            • HTA-Information Service Rapid Reviews
                              • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                • Horizon Scanning of Medicines - Reports and Fact Sheets
                                  • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                    • Evaluation of individual medical procedures - Reports
                                      • All projects in an overview
                                        Video
                                        Video: What is HTA?    
                                        • Home
                                        • Research Projects
                                        • Synopsis of completed research projects
                                        • Molecular genetic diagnostics as a triage mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)

                                        Molecular genetic diagnostics as a triage mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)

                                        Adobestock-64053191-von-zerbor
                                        Research areas: Prevention and screening, Health economics

                                        Project team: Christoph Strohmaier

                                        Project lead: Melanie Walter (part 1), Christoph Strohmaier (part 2)
                                        Duration: May 2020 – October 2020
                                        Language: English (with German summary)

                                        Publication: HTA Project report No. 130: http://eprints.aihta.at/1281/

                                         

                                        Background:

                                        The so-called personalised medicine or precision health care (PM/PHC) are domains that gradually take roots in the medical field influencing the decisions and behaviour of clinicians, the pharmaceutical industry, patients, payers, decision makers, and the functioning of the health system in general. These fields are strongly driven by new diagnostics and therapeutics, which - based on biomarkers, genetic, phenotypic or psychosocial characteristics - distinguish an individual patient from other patients with similar clinical conditions and thus form risk-based strata [1]. Molecular genetic tests are an increasingly important instrument of diagnostics, on the one hand for the definitive diagnosis of a disease and on the other hand as a prerequisite (companion diagnostics) for therapy with specifically effective drugs (prognostics). Often, however, the focus is not only on the genetic constitution of the affected patients themselves, but also on the resulting consequences for their offspring and relatives (prediction). In oncology and neurology, molecular genetic diagnostic, prognostic as well as predictive tests have been established for years and are widely used.

                                        Due to the discovery of functional gene sequences related to familial hypercholesterolemia (FH) (LDLR, APO-B, PCSK9), molecular genetic testing is becoming increasingly important in cardiology, particularly as a triage mechanism for risk stratification in the prevention of (arteriosclerotic) cardiovascular diseases. FH is a widespread inheritable disorder of the lipid metabolism that increases the risk of (arteriosclerotic) cardiovascular events, even at a young age [2]. In Austria, a molecular genetic confirmation of the presence of a mutation on the FH-associated genes is not mandatory for diagnosis. In addition to a definitive diagnosis, an expansion of molecular genetic testing may help to more effective cascade tests of relatives at risk, the initiation of therapies in earlier years as well as to improved and more efficient therapeutic decisions in general (e.g. a decision on the use of PCSK9 inhibitors) [2]. Against this background, organisational-logistical questions as well as ethical aspects of the implementation of a systematic test, but also far-reaching economic effects, have to be considered.

                                        Project objectives and research questions:

                                        The aim of the project is to provide a decision document for the implementation of (predictive) molecular genetic diagnostics as a triage mechanism in cardiology using the example of the FH.  The following research questions are to be answered:

                                        • Q1: Which test strategies to diagnose FH exist and which are recommended by (inter-) national associations?
                                        • Q2: What are the organisational/logistical requirements and necessities for the different test strategies?
                                        • Q3: Which ethical and regulatory aspects have to be considered in (predictive) molecular genetic diagnostics?
                                        • Q4: Which test strategy is currently used in Austria?
                                        • Q5: What are the economic implications of the different test strategies?

                                        Methods:

                                        The following methods are used to answer the research questions:

                                        • Q1: Systematic synthesis of test strategies in a country comparison (without evaluating the effectiveness and the benefit of the respective test strategy): Overview of guidelines, algorithms, and recommendations from expert societies on how to proceed in dealing with the diagnosis of FH as well as the prescription and response control of PCSK9 inhibitors in the presence of a FH-diagnosis.
                                        • Q2: Extraction of the organisational processes, description of the actors involved and their interactions as well as the qualitative deduction of the logistic requirements and necessities of the respective test strategy.
                                        • Q3: Systematic synthesis of ethical and regulatory aspects: Overview of recommendations for dealing with (predictive) genetic information and extraction of relevant arguments and aspects (based on the Hofmann question catalogue [3]) in form of a perspective-sensitive matrix.
                                        • Q4: Analysis of the current processes in Austria and contrasting them to other test strategies, including contacting experts from the field of cardiology and human genetics as well as patient organisations.
                                        • Q5: Economic extrapolation of the cost implications of different test strategies, organisational models and follow-up costs in form of a scenario analysis respectively a budget impact analysis; if accessible, Austria-specific costs based on tariff catalogues and administrative data are used.

                                        For Q1, Q3 and Q5, systematic searches supplemented by iterative manual searches (in German and English) will be conducted in several databases (Medline, Embase, G-I-N guidelines, Trip Database, EconLit, RePec etc.).

                                        In addition, for Q1

                                        • official public health institutions (e.g. NHS, G-BA, KBV, KV, social insurances)
                                        • expert societies (e.g. AWMF, AHA, NLA)
                                        • HTA, EbM institutions (e.g. NICE, NIH, ethics councils)

                                        for Q3

                                        • ethics-related databases (e.g. Belit, CINAHL, EthxWeb, ETHICSWEB, PsycINFO, Scopus)
                                        • guidelines from national genetics networks
                                        • stakeholder websites

                                        and for Q4

                                        • sources of Austria-specific guidelines, national expert societies, policy documents, etc.

                                        will be searched for relevant literature.

                                        For Q5, additional administrative data (tariff regulations, claims data, etc.) and the unit cost database of the Department for Health Economics at the Med-Uni Vienna will be used as data sources for cost calculations and exploration of the budget consequences.

                                        PICO framework/scope:

                                        Population

                                        ·    Patients with clinically and/or genetically diagnosed familial hypercholesterolemia

                                        ·    Patients with

                                        -     primary hypercholesterolemia

                                        -     primary hypercholesterolemia and diagnostically confirmed coronary artery disease and/or peripheral arterial disease and/or cerebral arterial disease

                                        -     suspected FH

                                        ·    Family/relatives of the above patient groups

                                        Intervention

                                        (Predictive) Molecular genetic diagnosis of FH (mutations in FH-associated genes (LDLR, APO-B, PCSK9))

                                        Comparators

                                        Standard clinical diagnosis of FH

                                        Outcomes

                                        ·    Q1 und Q4: organisational and logistical aspects of different test strategies:

                                        -     Timing of testing

                                        -     Data documentation

                                        -     Involved stakeholders

                                        -     Quality standards

                                        -     Etc.

                                        ·    Q3: ethical and regulatory aspects of (predictive) molecular genetic diagnostics:

                                        -     Benefit-harm balance

                                        -     Autonomy

                                        -     Respect for persons

                                        -     Fair access to technology

                                        -     Etc.

                                        ·    Q5: cost implications and differences of the test strategies, organisational models, and their follow-up costs

                                        Setting

                                        Ambulatory/outpatient setting (extramural)

                                        Study design

                                        No restrictions

                                        Publication period

                                        No restrictions

                                        Language

                                        English, German

                                        All work steps are carried out according to the 4-eyes principle (MW, CS); the results are subjected to an internal and external review.

                                        Time schedule:

                                        Period

                                        Activity

                                        May 2020

                                        Scoping, preparation of the project protocol

                                        May to June 2020

                                        Literature search, selection of literature, hand search, contact with experts

                                        June to August 2020

                                        Data extraction, economic scenario analysis/budget impact analysis, conducting the experts interviews

                                        July to September 2020

                                        Writing/drafting the report

                                        October 2020

                                        Internal and external review, finalisation

                                        References:
                                        [1]        Jameson J. L. and Longo D. L. Precision medicine--personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229-2234. Epub 2015/05/28. DOI: 10.1056/NEJMsb1503104.
                                        [2]        Sturm A. C., Knowles J. W., Gidding S. S., Ahmad Z. S., Ahmed C. D., Ballantyne C. M., et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(6):662-680. Epub 2018/08/04. DOI: 10.1016/j.jacc.2018.05.044.
                                        [3]        Hofmann B., Droste S., Oortwijn W., Cleemput I. and Sacchini D. Harmonization of ethics in health technology assessment: a revision of the Socratic approach. Int J Technol Assess Health Care. 2014;30(1):3-9. Epub 2014/02/07. DOI: 10.1017/S0266462313000688.

                                        • News
                                          • Announcements
                                            • Events
                                              • Newsletter
                                                • Press release on our reports
                                                  • Press photos
                                                  • About us
                                                    • Evaluation
                                                      • History
                                                        • Methods
                                                          • Team
                                                            • Shareholder & organization chart
                                                              • Stakeholder involvement
                                                                • Press clippings
                                                                • Research areas
                                                                  • Oncology
                                                                    • High tech medicine
                                                                      • Rehabilitation and occupational therapy
                                                                        • Prevention and screening
                                                                          • Psychological & psychiatric interventions
                                                                            • Health economics
                                                                              • European collaboration
                                                                                • HTA-methods & steering instruments
                                                                                  • Complementary medicine
                                                                                  • Research Projects
                                                                                    • Synopsis of current research projects
                                                                                      • Synopsis of completed research projects
                                                                                        • HTA-Information Service Rapid Reviews
                                                                                          • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                            • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                              • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                                • Evaluation of individual medical procedures - Reports
                                                                                                  • All projects in an overview
                                                                                                  • Publications
                                                                                                    • Repository
                                                                                                      • HTA-Newsletter
                                                                                                        • Annual Reports
                                                                                                        • Search
                                                                                                          Netzwerk
                                                                                                          • Eunethta
                                                                                                          • Ebm
                                                                                                          • Inahta
                                                                                                          • Dexhelpp
                                                                                                          Shareholder
                                                                                                          • Bmfg
                                                                                                          • Sv
                                                                                                          • Wgfond
                                                                                                          • Noe
                                                                                                          • Ooghfond
                                                                                                          • Ghls
                                                                                                          • Tirol
                                                                                                          • Vorarlberg
                                                                                                          • Kghfond
                                                                                                          • Ghpf
                                                                                                          • Burgef
                                                                                                          • Contact
                                                                                                            • Imprint
                                                                                                              • Privacy Notice
                                                                                                                • Newsletter
                                                                                                                  • Sitemap
                                                                                                                    © 2023 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                    • Log in